MARKET

BRRGD

BRRGD

Oncoinvent ASA
EXMKT
1.770
NaN%
Closed 09:30 02/06 EST
OPEN
--
PREV CLOSE
0.025
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
2.500
52 WEEK LOW
1.770
MARKET CAP
7.93M
P/E (TTM)
-0.1013
1D
5D
1M
3M
1Y
5Y
1D
Oncoinvent Sets Out 2025–2026 Financial Reporting Calendar and Quarterly Market Updates
TipRanks · 4d ago
Oncoinvent Expands Phase 2 Radspherin Trial with New Sites and First Patient Enrollment
TipRanks · 01/29 07:48
Oncoinvent Advances Radspherin® Phase 2 Trial in Advanced Ovarian Cancer: What Investors Should Watch
TipRanks · 01/23 16:34
Oncoinvent Registers Share Capital Increase Ahead of Reverse Share Split
TipRanks · 01/15 09:35
Oncoinvent Launches 100-for-1 Reverse Share Split and New ISIN on Oslo Bourse
TipRanks · 01/14 15:02
Oncoinvent Grants New CEO Multiyear Share Option Package Tied to Long-Term Growth
TipRanks · 01/13 08:04
Oncoinvent Reshapes Capital Structure After Extraordinary General Meeting
TipRanks · 01/08 13:03
Oncoinvent Revamps Option Scheme and Issues New Grants After BerGenBio Merger
TipRanks · 12/22/2025 17:34
More
About BRRGD
Oncoinvent ASA, formerly Bergenbio ASA, is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. The Company is based in Bergen, Norway with a subsidiary in Oxford, UK.

Webull offers Oncoinvent ASA stock information, including EXMKT: BRRGD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRRGD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRRGD stock methods without spending real money on the virtual paper trading platform.